T-cell Response – Page 29 – Communicable Diseases Research

Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial

건강한 성인에서 HIV를 예방하기 위한 아데노 관련 바이러스 매개 면역 예방: 1상 무작위 대조 시험

Article

Published on 2019-03-152022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

저위험 HIV 감염되지 않은 남아프리카 성인을 대상으로 한 아형 C ALVAC-HIV 및 2가 아형 C gp120/MF59 HIV-1 백신: 1/2상 시험

Article

Published on 2018-06-182022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] 95% CI added adjuvant advancement African allergy Antigen assigned binding antibody CD4+ T-cell changed circulating clinical Community component computer-generated Critical double-blind trial Efficacy enrolled exceeded Express finding foundation funding glycoprotein gp120 HIV HIV infection HIV vaccine HIV-1 HIV-uninfected IgG IgG response immune response immune responses immunogenicity IMPROVE Infectious disease Infectious diseases Intramuscular injection investigators Melinda Gate Melinda Gates MF59 network NIAID outcome participant per-protocol per-protocol analysis Placebo predicted Primary outcomes Protein provided random randomisation randomised controlled Randomly recipient regimen Registered registry reported Research responders response risk significantly higher South South Africa strain Strains subtype T-cell Response tested the vaccine threshold titre Trial vaccination Vaccine Vaccine development was done
[DOI] 10.1016/S2352-3018(18)30071-7 PMC 바로가기 [Article Type] Article

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial

신생아 MVA85A 백신 접종 및 인간 면역결핍 바이러스에 감염된 산모의 유아를 위한 선택적 지연 Bacille Calmette-Guerin의 안전성 및 면역원성: 2상 무작위, 대조 시험

Articles and Commentaries

Published on 2018-02-152022-09-06
Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease,

[키워드] acquisition Ag85A age appear ARMS bacille Calmette-Guérin BCG BCG vaccination boost candidate CD4 CD4+ T cell CD4+ T cells CD4+ T-cell clinical control arm Controlled Delayed disease double-blind ENhance enrolled excluded Follow-up followed by functional HIV HIV infection HIV-exposed infants HIV-uninfected Human Human immunodeficiency virus IFNγ immune response immunodeficiency virus immunogenicity Infant interfere interferon gamma life magnitude memory MVA85A New Newborn no significant difference Phase 2 phenotype potential risk profiles PROTECT randomized, controlled trial reactogenicity event Registration response Result Safe Safety selective Serious Adverse Events significantly higher subsequent T cells T-cell Response tested Tuberculosis tuberculosis disease tuberculosis vaccine vaccination Vaccination strategy vaccinees
[DOI] 10.1093/cid/cix834 PMC 바로가기 [Article Type] Articles and Commentaries

A whole-killed, blood-stage lysate vaccine protects against the malaria liver stage

article

Published on 2017-01-312024-09-01
Journal: Parasite Immunology [Category] 말라리아,

[키워드] antibody blood stage liver stage T-cell Response whole-killed blood-stage lysate vaccine
[Article Type] article

Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions

Article

Published on 2016-12-152023-06-24
Journal: The Journal of Infectious Diseases [Category] 신종인플루엔자,

[키워드] antigenic variation avian influenza A(H7N9) virus cross-reactivity Structure T-cell Response
[DOI] 10.1093/infdis/jiw471

Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases

Research Article

Published on 2015-12-072022-10-28
Journal: PLoS ONE [Category] Coronavirus,

[키워드] alleles Analysis B-cell B-cell epitope candidate Cellular immune response Coverage CTL CTL epitope CTL epitopes cytotoxic T lymphocyte Diseases dominant effective elicit epitope helper T-cell epitope helper T-cell epitopes HLA binding Immune Epitope Database Immunity immunogen induce Infectious disease linear majority mapped MERS MERS-CoV Middle East neutralizing antibody nucleocapsid pandemic pathogen peptide Population Protective protective neutralizing antibody Protein provide public health Region respiratory syndrome coronavirus screened Screening screening strategy selected sequence T-cell T-cell Response target the N protein Vaccine vaccine candidates Vaccine development was performed
[DOI] 10.1371/journal.pone.0144475 PMC 바로가기 [Article Type] Research Article

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

HIV-1에 감염된 건강한 성인에서 후보 결핵 백신 MVA85A의 안전성, 면역원성 및 효능: 무작위, 위약 대조, 2상 시험

Articles

Published on 2015-03-012022-09-06
Journal: The Lancet. Respiratory Medicine [Category] Communicable Disease,

[키워드] 1:1 95% CI absence active tuberculosis adverse event Antigen antigen 85A antigen 85A-specific T-cell response antiretroviral Antiretroviral therapy assigned assist baseline baseline CD4 block blocks booster Cape CD4 count CD4 counts Cell clinical defined detect detectable Developing disease double-blind effective Efficacy eligible Eligible participants enrolled enrolment European Evidence evidence of expressing finding first vaccination foundation funding gold greater Group allocation had no healthy HIV-1 HIV-1 infection immunogenic immunogenicity include increased risk Infection injection intradermal injections investigators isoniazid isoniazid prophylaxis Laboratory latent tuberculosis latent tuberculosis infection M tuberculosis Measures Melinda Gate Melinda Gates modified vaccinia virus MVA85A Mycobacterium tuberculosis nine no evidence of Nurses occurred outcome participant partnership peaked per-protocol analysis per-protocol population Phase 2 phase 2 trial Placebo placebo group placebo-controlled positive Potential Prophylaxis protocol QuantiFERON QuantiFERON-TB Gold In-Tube randomisation randomised Randomly receive receiving Registered reported Safe Safety safety analysis second vaccination secondary Secondary outcomes sequence Serious Adverse Event Serious Adverse Events significant increase South Africa stratified subset T-cell Response the placebo group therapy town Treatment Trial Tuberculosis tuberculosis disease tuberculosis vaccine undetectable vaccination Vaccine vaccine efficacy vaccine-induced immune response Viral Viral load Wellcome Trust were assessed
[DOI] 10.1016/S2213-2600(15)00037-5 PMC 바로가기 [Article Type] Articles

Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen

Research Article

Published on 2014-11-182022-10-28
Journal: PLoS ONE [Category] Coronavirus,

[키워드] adjuvant antibody Antigen BALB/c mice Cell-mediated immunity cellular immune responses cellular immunity Combination CpG Critical cytokine production delivery effective elicited ELISpot assay evaluated Freund’s adjuvant humoral Humoral immunity hydroxide hypothesised IFA IFN-γ IgG immune response Immunity immunized immunogenic IMPROVE indicated intramuscularly investigated MERS-CoV MERS-CoV RBD mice Middle East Modification murine Neutralizing antibodies neutralizing antibody offered pandemic Protein purified RBD regimen respiratory respiratory syndrome coronavirus robust route rRBD spot-forming cell subunit T-cell Response the receptor-binding domain vaccination Vaccine was tested
[DOI] 10.1371/journal.pone.0112602 PMC 바로가기 [Article Type] Research Article

Enhanced CD8 T-cell anti-viral function and clinical disease in B7-H1-deficient mice requires CD4 T cells during encephalomyelitis

Research

Published on 2012-12-142022-10-30
Journal: Journal of Neuroinflammation [Category] Coronavirus,

[키워드] absence accelerate Activation Affect Analysis Anti-viral anti-viral activity Axonal damage bystander CD4 CD4 T cell CD4 T-cell CD4⁺ and CD8⁺ T cells CD8 CD8 T cell CD8 T-cell Central nervous system clinical disease CNS compared contribute coronavirus Cytometry decrease Encephalomyelitis ENhance enhanced evaluated Ex vivo expression Flow Gene expression analysis Gliatropic coronavirus help histocompatibility complex IFN-γ IL-21 impede increase Increased Infected Inflammation inhibitory inhibitory signal interactions interferon less Local Lymph node macrophages mice microglia MONITOR morbidity mRNA nitric oxide overcome pathology Population purified reduced regulated Result T helper T-cell T-cell Response target cells upregulation viral control was used were infected
[DOI] 10.1186/1742-2094-9-269 PMC 바로가기 [Article Type] Research

The expression and antigenicity of a truncated spike-nucleocapsid fusion protein of severe acute respiratory syndrome-associated coronavirus

Research Article

Published on 2008-11-282022-10-28
Journal: BMC Microbiology [Category] Coronavirus,

[키워드] absence analyzed antibody Antigen antigenicity antiviral efficacy assays BALB/c mice cloned coronavirus cross-reactivity determined diagnostic effective drugs effective vaccine ELISA Escherichia coli evaluate expressed expression expression vector fluorescent fusion protein HCoV 229E human coronavirus human coronaviruses humoral IFA immunization immunized mice immunoblot induce inhibit injected injection intranasally Laboratory test management mice National neutralization nucleocapsid OC43 Protein Quantitative reactivity Result RT-PCR SARS patient SARS virus Sensitivity and specificity sera T cell proliferation T-cell analysis T-cell Response vaccine candidate Viral load virus replication was performed
[DOI] 10.1186/1471-2180-8-207 PMC 바로가기 [Article Type] Research Article